The allosteric inhibitor ABL001 enables dual targeting of BCR–ABL1

Andrew A. Wylie(Novartis (United States)), Joseph Schoepfer(Novartis (Switzerland)), Wolfgang Jahnke(Novartis Institutes for BioMedical Research), Sandra W. Cowan‐Jacob(Novartis Institutes for BioMedical Research), Alice Loo(Novartis (United States)), Pascal Furet(Novartis (Switzerland)), Andreas L. Marzinzik(Novartis (Switzerland)), Xavier Pellé(Novartis (Switzerland)), Jerry Donovan(Novartis (United States)), Wenjing Zhu(Novartis (United States)), Silvia Buonamici(Novartis (United States)), Amr Hassan(Novartis (United States)), Franco Lombardo(Novartis (United States)), Varsha Iyer(Novartis Institutes for BioMedical Research), Michael R. Palmer(Novartis (United States)), Giuliano Berellini(Novartis (United States)), Stephanie Dodd(Novartis (United States)), Sanjeev Thohan(Novartis (United States)), Hans Bitter(Novartis (United States)), Susan Branford(Centre for Cancer Biology), David M. Ross(South Australia Pathology), Timothy P. Hughes(South Australian Health and Medical Research Institute), Lilli Petruzzelli(Novartis (United States)), K. Gary J. Vanasse(Novartis (United States)), Markus Warmuth(Novartis (United States)), Francesco Hofmann(Novartis (Switzerland)), Nicholas Keen(Novartis (United States)), William R. Sellers(Novartis (United States))
Nature
March 1, 2017
10.1038/nature21702
Cited by 591

Abstract

Related Papers

No related papers found

Powered by citation graph analysis